Comparison

GYKI 52466 hydrochloride European Partner

Item no. ALO-G-125-5mg
Manufacturer Alomone
CASRN 192065-56-8
Amount 5 mg
Quantity options 100 mg 10 mg 25 mg 50 mg 5 mg
Category
Type Small Molecules
Format Lyophilized
Specific against other
Purity >96.6%
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Shipping Condition Room temperature
Available
Manufacturer - Type
Non Antibodies
Manufacturer - Category
S. Molecules
Manufacturer - Targets
AMPA/Kainate receptors
Country of Origin
Israel
Shipping Temperature
Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C
Storage Conditions
Storage as Solution: Up to four weeks at 4°C or three months at -20°C. - Storage after Reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods (up to 6 months), small aliquots should be stored at -20°C. We do not recommend storing the product in working solutions for longer than a few days. Avoid multiple freeze-thaw cycles.
Molecular Weight
329, 78
Manufacturer - Format
Lyophilized powder.
Short description
An Antagonist of AMPA and Kainate Receptors
Description
An Antagonist of AMPA and Kainate Receptors
Reconstitution
30 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
PH
7, 4
UNSPSC
41116134
Effective Concentration
300 nM - 300 µM.
Activity
GYKI 52466 is a selective allosteric AMPA/kainate receptor antagonist, with an IC50 of ~10 μM for AMPA induced currents in cultured superior colliculus neurons1.
Solubility
30 mM in DMSO. Centrifuge all product preparations before use (10000 x g for 1 min).
Bioassay tested
Yes
Chemical Name
1-(4-Aminophenyl)-4-methyl-7, 8-methylenedioxy-5H-2, 3-benzodiazepine hydrochloride.
Scientific Background
GYKI 52466 hydrochloride is a non-competitive AMPA and kainate receptor antagonist. It blocks GluK3 homomeric receptors with an IC50 of 63 μM and GluK2b(R)/GluK3 heteroreceptors with an IC50 of 32 μM at high concentrations. GYKI 52466 has been reported to prevent the excitotoxic action of high extracellular glutamate levels due to its potent non-competitive AMPA receptor antagonistic effect. It has been demonstrated histologically that GYKI 52466 has neuroprotective actions in experimental models of global and focal cerebral ischaemia. The compound was widely investigated in experimental seizure models, where it provided effective protection against convulsions evoked by chemical agents such as AMPA or kainate, electroshock and audiogenic stimulation1.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close